HRP20200307T1 - Novi derivati pirolidina - Google Patents
Novi derivati pirolidina Download PDFInfo
- Publication number
- HRP20200307T1 HRP20200307T1 HRP20200307TT HRP20200307T HRP20200307T1 HR P20200307 T1 HRP20200307 T1 HR P20200307T1 HR P20200307T T HRP20200307T T HR P20200307TT HR P20200307 T HRP20200307 T HR P20200307T HR P20200307 T1 HRP20200307 T1 HR P20200307T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- diabetes
- trifluoromethyl
- treatment
- compound
- Prior art date
Links
- 150000003235 pyrrolidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 2
- -1 (1-cyanocyclopropyl)-amide (2S, 4R)-4-[4-(5-methyl-tetrazol-2-yl)-2-trifluoromethyl-benzenesulfonyl]-1-(1-trifluoromethyl-cyclopropanecarbonyl)-pyrrolidine- 2-carboxylic acids Chemical class 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 210000000702 aorta abdominal Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000008076 immune mechanism Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Claims (5)
1. Spoj, naznačen time, da je predstavljen formulom
(1-cijano ciklopropil)-amid (2S, 4R)-4-[4-(5-metil-tetrazol-2-il)-2-trifluorometil-benzensulfonil]-1-(1-trifluorometil-ciklopropankarbonil)-pirolidin-2-karboksilne kiseline
ili njegova farmaceutski prihvatljiva sol ili njegov ester.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je za uporabu kao terapeutski aktivna tvar.
3. Farmaceutski pripravak, naznačen time, da sadrži spoj prema patentnom zahtjevu 1 i terapeutski inertni nosač.
4. Spoj prema patentnom zahtjevu 1, naznačen time, da se upotrebljava za liječenje ili profilaksu dijabetesa, ateroskleroze, aneurizme trbušne aorte, periferne arterijske bolesti, raka, smanjenja kardiovaskularnih događaja u kroničnoj bolesti bubrega, dijabetičke nefropatije, dijabetičke retinopatije ili senilne makularne degeneracije.
5. Spoj prema patentnom zahtjevu 1, naznačen time, da se upotrebljava u liječenju bolesti posredovanih imunološkim mehanizmima, posebice reumatoidnog artritisa, multiple skleroze, Sjorgen sindroma, eritematoznog lupusa, neuropatske boli, dijabetesa tipa I, astme te alergija i kožnih imunoloških bolesti.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16157679 | 2016-02-26 | ||
| EP17705662.9A EP3419970B1 (en) | 2016-02-26 | 2017-02-22 | Novel pyrrolidine derivatives |
| PCT/EP2017/053967 WO2017144483A1 (en) | 2016-02-26 | 2017-02-22 | Novel pyrrolidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200307T1 true HRP20200307T1 (hr) | 2020-06-12 |
Family
ID=55443159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200307TT HRP20200307T1 (hr) | 2016-02-26 | 2020-02-24 | Novi derivati pirolidina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10689339B2 (hr) |
| EP (1) | EP3419970B1 (hr) |
| JP (1) | JP6952044B2 (hr) |
| KR (1) | KR20180111862A (hr) |
| CN (1) | CN108699044B (hr) |
| AR (1) | AR107717A1 (hr) |
| AU (1) | AU2017224343B2 (hr) |
| CA (1) | CA3011652C (hr) |
| CL (1) | CL2018002347A1 (hr) |
| CO (1) | CO2018007756A2 (hr) |
| CR (1) | CR20180404A (hr) |
| DK (1) | DK3419970T3 (hr) |
| ES (1) | ES2775781T3 (hr) |
| HR (1) | HRP20200307T1 (hr) |
| HU (1) | HUE047842T2 (hr) |
| IL (1) | IL260130B (hr) |
| LT (1) | LT3419970T (hr) |
| MA (1) | MA43667B1 (hr) |
| MX (1) | MX2018009638A (hr) |
| MY (1) | MY196560A (hr) |
| PH (1) | PH12018501585B1 (hr) |
| PL (1) | PL3419970T3 (hr) |
| PT (1) | PT3419970T (hr) |
| RS (1) | RS59938B1 (hr) |
| RU (1) | RU2736498C1 (hr) |
| SG (1) | SG11201807074VA (hr) |
| SI (1) | SI3419970T1 (hr) |
| TW (1) | TWI740903B (hr) |
| UA (1) | UA122084C2 (hr) |
| WO (1) | WO2017144483A1 (hr) |
| ZA (1) | ZA201804120B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102553613B1 (ko) | 2017-01-24 | 2023-07-07 | 아스테라스 세이야쿠 가부시키가이샤 | 페닐디플루오로메틸 치환 프롤린아미드 화합물 |
| AR114732A1 (es) | 2018-09-18 | 2020-10-07 | Hoffmann La Roche | Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120911A1 (es) * | 2009-04-20 | 2012-08-06 | Hoffmann La Roche | Derivados de prolina como inhibidores de catepsina |
| PL2776392T3 (pl) * | 2011-11-11 | 2016-11-30 | Sposób wytwarzania pochodnych 1-acylo-4-fenylosulfonyloprolinoamidu i nowe związki pośrednie | |
| JP2014533707A (ja) * | 2011-11-25 | 2014-12-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | カテプシンの阻害剤としての新規ピロリジン誘導体 |
| CN104114068B (zh) * | 2011-12-09 | 2017-07-11 | W.C.布拉德利公司 | 具有可调整的加热特征的烹饪炉排 |
| CA2859928A1 (en) * | 2012-02-17 | 2013-08-22 | F. Hoffmann-La Roche Ag | Novel pyrrolidine derivatives |
| KR20150044947A (ko) * | 2012-08-21 | 2015-04-27 | 에프. 호프만-라 로슈 아게 | 신규한 피리딘 유도체 |
-
2017
- 2017-02-22 DK DK17705662.9T patent/DK3419970T3/da active
- 2017-02-22 MA MA43667A patent/MA43667B1/fr unknown
- 2017-02-22 UA UAA201809397A patent/UA122084C2/uk unknown
- 2017-02-22 LT LTEP17705662.9T patent/LT3419970T/lt unknown
- 2017-02-22 HU HUE17705662A patent/HUE047842T2/hu unknown
- 2017-02-22 MX MX2018009638A patent/MX2018009638A/es unknown
- 2017-02-22 EP EP17705662.9A patent/EP3419970B1/en active Active
- 2017-02-22 JP JP2018541661A patent/JP6952044B2/ja active Active
- 2017-02-22 AU AU2017224343A patent/AU2017224343B2/en active Active
- 2017-02-22 RU RU2018133640A patent/RU2736498C1/ru active
- 2017-02-22 MY MYPI2018001465A patent/MY196560A/en unknown
- 2017-02-22 SI SI201730195T patent/SI3419970T1/sl unknown
- 2017-02-22 KR KR1020187024347A patent/KR20180111862A/ko not_active Application Discontinuation
- 2017-02-22 CR CR20180404A patent/CR20180404A/es unknown
- 2017-02-22 RS RS20200183A patent/RS59938B1/sr unknown
- 2017-02-22 ES ES17705662T patent/ES2775781T3/es active Active
- 2017-02-22 CA CA3011652A patent/CA3011652C/en active Active
- 2017-02-22 WO PCT/EP2017/053967 patent/WO2017144483A1/en active Application Filing
- 2017-02-22 CN CN201780013397.XA patent/CN108699044B/zh active Active
- 2017-02-22 PT PT177056629T patent/PT3419970T/pt unknown
- 2017-02-22 SG SG11201807074VA patent/SG11201807074VA/en unknown
- 2017-02-22 PL PL17705662T patent/PL3419970T3/pl unknown
- 2017-02-24 AR ARP170100467A patent/AR107717A1/es unknown
- 2017-02-24 TW TW106106388A patent/TWI740903B/zh active
-
2018
- 2018-06-19 IL IL260130A patent/IL260130B/en active IP Right Grant
- 2018-06-20 ZA ZA2018/04120A patent/ZA201804120B/en unknown
- 2018-07-25 PH PH12018501585A patent/PH12018501585B1/en unknown
- 2018-07-26 CO CONC2018/0007756A patent/CO2018007756A2/es unknown
- 2018-08-16 CL CL2018002347A patent/CL2018002347A1/es unknown
- 2018-08-24 US US16/111,721 patent/US10689339B2/en active Active
-
2020
- 2020-02-24 HR HRP20200307TT patent/HRP20200307T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| PE20191406A1 (es) | N-[4-fluoro-5-[[(2s, 4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| JP2016027060A5 (hr) | ||
| HRP20200307T1 (hr) | Novi derivati pirolidina | |
| PH12017501421A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| WO2013002580A3 (ko) | 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물 | |
| MX2015013893A (es) | Nuevo derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico, metodo de preparacion del mismo y composicion farmaceutica para la prevencion y tratamiento de la enfermedad metabolica que incluye el mismo como ingrediente activo. | |
| RU2016150535A (ru) | Новые соединения | |
| BR112018073951A2 (pt) | forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
| JP2016511753A5 (hr) | ||
| JP2016510326A5 (hr) | ||
| JP2016521279A5 (hr) | ||
| WO2012116176A3 (en) | Asymmetric ureas and medical uses thereof | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| JP2018115221A (ja) | 網脈絡膜障害の抑制剤 | |
| RU2012157328A (ru) | Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера | |
| JP2017505809A5 (hr) | ||
| EA201270653A1 (ru) | Антагонист dpи его применение | |
| RU2015156417A (ru) | Лосмапимод для применения в лечении гломерулярного заболевания | |
| JP2016523943A5 (hr) | ||
| WO2016165205A8 (zh) | 一种新型的bcr-abl激酶抑制剂 | |
| RU2014102743A (ru) | Амидное производное, замещенное n-гетероциклическим кольцом |